Atara Biotherapeutics Inc (NAS:ATRA)
$ 10.28 -1.35 (-11.61%) Market Cap: 58.33 Mil Enterprise Value: 83.40 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 40/100

Q1 2019 Atara Biotherapeutics Inc Earnings Call Transcript

May 09, 2019 / 12:30PM GMT
Release Date Price: $680.5 (-20.60%)
Operator

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Atara Biotherapeutics First Quarter 2019 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference call will be recorded.

I will now turn the call over to Dr. John Craighead, Vice President of Investor Relations and Corporate Communications of Atara Biotherapeutics. Please go ahead, sir.

John Craighead
Atara Biotherapeutics, Inc. - VP of IR & Corporate Communications

Thank you, operator. Good morning, everyone, and welcome to the Atara First Quarter 2019 Financial Results and Corporate Update Conference Call. Earlier this morning, we issued a press release providing an overview of the company's first quarter 2019 financial results and recent operational progress. Please note that this press release is available in the Investors & Media section at atarabio.com.

I'm joined on the call today by Dr. Isaac Ciechanover, President and Chief Executive Officer; Dr. Dietmar Berger, Global Head of R&D; and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot